Spartan Wealth Advisory Services LLC Makes New $406,000 Investment in Novo Nordisk A/S $NVO

Spartan Wealth Advisory Services LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,057 shares of the company’s stock, valued at approximately $406,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S in the fourth quarter worth $25,000. WealthCollab LLC raised its stake in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares in the last quarter. American National Bank & Trust bought a new position in Novo Nordisk A/S during the fourth quarter valued at $28,000. Maseco LLP purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $29,000. 11.54% of the stock is currently owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Wolfe Research started coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Finally, Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Five equities research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $50.29 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a market capitalization of $224.56 billion, a P/E ratio of 11.81, a price-to-earnings-growth ratio of 4.59 and a beta of 0.77. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $71.79. The company’s 50-day moving average is $46.09 and its 200 day moving average is $45.79.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Research analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.